Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
September 15 2014 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert
F. Apple has been promoted to Chief Operating Officer effective
immediately. The Company also announced that a retained search has
begun to fill the position of Chief Financial Officer. Until the
position is filled, Mr. Apple will continue to serve as the
Company’s Chief Financial Officer as he has since he joined Antares
Pharma in 2006.
Eamonn P. Hobbs, President and Chief Executive Officer of the
Company, stated, “Bob’s responsibilities have expanded since he
joined the Company to include oversight of the Parenteral Products
Group, and we believe that elevating him to Chief Operating Officer
will leverage his prior commercial background and his technical
expertise in the combination drug/device area, helping the Company
increase overall efficiency.” Mr. Hobbs continued, “We congratulate
Bob on his promotion and look forward his contributions to Antares
Pharma’s future strategic growth.”
Mr. Apple joined the Company in February 2006 as Senior Vice
President and Chief Financial Officer and was promoted to Executive
Vice President, Chief Financial Officer and President of the
Parenteral Products Group in 2008. Prior to joining the Company,
Mr. Apple served as Chief Operating and Financial Officer at InKine
Pharmaceutical Company, Inc. (“InKine”) from 2003 to 2005, and
Chief Financial Officer from 1997 to 2002. In his role as Chief
Operating Officer, Mr. Apple was responsible for building a 60
person in-house sales team and grew product sales until the
ultimate acquisition of InKine by Salix Pharmaceuticals, Inc. In
his role as Chief Operating Officer, Mr. Apple will be responsible
for all aspects of operations at Antares Pharma including sales,
marketing, manufacturing and product development.
“I’m excited to assume the newly created role of Chief Operating
Officer,” stated Robert F. Apple. “Antares Pharma has grown from an
innovator of novel technologies to a combination drug/device
commercial company in the eight plus years I’ve been here. I
believe that the combination of my commercial, technical and
financial backgrounds will provide a great source of experience as
we move Antares toward becoming a fully integrated pharmaceutical
company.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products. The Company markets OTREXUP™
(methotrexate) injection for the treatment of adults with severe
active rheumatoid arthritis and children with active polyarticular
juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to
dermatologists for adults with severe recalcitrant psoriasis.
Antares Pharma is also developing VIBEX® QS T for testosterone
replacement therapy. The Company's technology platforms include
VIBEX® disposable Medi-Jet, disposable multi-use pen injectors and
reusable needle-free injectors marketed as Tjet® and Zomajet® by
Teva Pharmaceutical Industries, Ltd (Teva) and Ferring
Pharmaceuticals (Ferring), respectively. Antares Pharma has a
multi-product deal with Teva that includes Tev-Tropin® [somatropin
(rDNA origin) for injection] human growth hormone (hGH), VIBEX®
epinephrine and several other products. In the U.S. Antares has
received FDA approval for Gelnique 3%™ (oxybutynin) gel, a
treatment for overactive bladder that is marketed by Actavis.
Elestrin® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and is marketed in the U.S. by Meda Pharma.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, including statements made with
respect to the contributions of Mr. Robert F. Apple to Antares
Pharma in the role of Chief Operating Officer and impact thereof,
and products in development; and other statements regarding matters
that are not historical facts, and involve predictions. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Such forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2013, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by law.
Antares Pharma, Inc.Jack Howarth, 609-359-3016Vice President,
Corporate Affairsjhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Oct 2023 to Oct 2024